Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis
Authors:
- Fredrik RomiFRFredrik Romi
- Geir Olve SkeieGSGeir Olve Skeie
- Christian VedelerCVChristian Vedeler
- Johan A AarliJAJohan A Aarli
- Francesco ZorzatoFZFrancesco Zorzato
- Nils Erik GilhusNGNils Erik Gilhus
- 1 November 2000
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 111 (1-2) , 169-176
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Antibody dependent cell-mediated cytotoxicity — an additional mechanism in human autoimmune myasthenia gravisJournal of Neuroimmunology, 1999
- INTRACELLULAR ANTIBODIES (INTRABODIES) FOR GENE THERAPY OF INFECTIOUS DISEASESAnnual Review of Microbiology, 1997
- Affinity of the interaction between Fcgamma receptor type III (FcγRIII) and monomeric human IgG subclasses. Role of FcγRIII glycosylationEuropean Journal of Immunology, 1997
- Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin 1.Journal of Clinical Investigation, 1997
- Ryanodine receptor antibodies are associated with severe myasthenia gravisEuropean Journal of Neurology, 1996
- Titin Antibodies in Patients with Late Onset Myasthenia Gravis: Clinical CorrelationsAutoimmunity, 1995
- Human IgG subclass pattern of inducing complement‐mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentrationEuropean Journal of Immunology, 1991
- CA-antibody: an immunological marker of thymic neoplasia in myasthenia gravis?Acta Neurologica Scandinavica, 1987
- Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications.Journal of Neurology, Neurosurgery & Psychiatry, 1978
- AN ASSESSMENT OF CHANGES IN THE COMPLEMENT LEVEL OF MYASTHENIC SERA*Annals of the New York Academy of Sciences, 1966